Search

Your search keyword '"Vastert, Sebastiaan J."' showing total 473 results
Start Over Author "Vastert, Sebastiaan J."
473 results on '"Vastert, Sebastiaan J."'

2. Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis

Author

Vastert, Sebastiaan J., Canny, Susan P., Canna, Scott W., Schneider, Rayfel, Mellins, Elizabeth D., Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Steinlein, Ortrud, Series Editor, Xiao, Junjie, Series Editor, Cron, Randy Q., editor, and Behrens, Edward M., editor

Published
2024
Full Text
View/download PDF

3. Serum proteomics reveals hemophagocytic lymphohistiocytosis-like phenotype in a subset of patients with multisystem inflammatory syndrome in children

Author

Tulling, Adam J., Holierhoek, Marloes G., Jansen-Hoogendijk, Anja M., Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J., Oostenbrink, Rianne, Buysse, Corinne M.P., Bannier, Michiel A.G.E., Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C., Jacobs, Monique A.M., Kamps, Arvid W.A., van der Linden, Jan W., Lebon, Ankie, Oudshoorn, Johanna H., Tramper-Stranders, Gerdien A., Vastert, Sebastiaan J., Wieringa, Jantien W., Terheggen-Lagro, Suzanne W.J., Wildenbeest, Joanne G., von Asmuth, Erik G.J., van den Akker, Erik B., van Gijn, Marielle E., Lugthart, Gertjan, and Buddingh, Emilie P.

Published
2024
Full Text
View/download PDF

8. Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children From Wild-type to Population Immunity: A Prospective Multicenter Cohort Study With Real-time Reporting

Author

Tulling, Adam J., Lugthart, Gertjan, Mooij, Miriam G., Brackel, Caroline L. H., Terheggen-Lagro, Suzanne W. J., Oostenbrink, Rianne, Buysse, Corinne M. P., Hashimoto, Simone, Armbrust, Wineke, Bannier, Michiel A. G. E., Bekhof, Jolita, van Gameren-Oosterom, Helma B., Hendriks, Han, van Houten, Marlies A., van der Linden, Jan W., Lebon, Ankie, van Onzenoort-Bokken, Lonneke, Tramper-Stranders, Gerdien A., van Veen, Mirjam, von Asmuth, Erik G. J., Buddingh, Emilie P., van der Aa, Leontien B., van Aerde, Koen J., Auffarth-Smedema, Bettina, Bart, Ingeborg Y., Beek, Cherise, Bechan, Gitanjali I., van den Berg, J. Merlijn, Boonstra, Venje H., Breukels, Mijke, Brinkman, Danielle M.C., Bruijning-Verhagen, Patricia C.J.L., de Crom, Stephanie C., Ernst-Kruis, Margot R., Fraaij, Pieter L.A., Goris, Joyce, Groeneweg, Michael, Gruppen, Mariken, Hammer, Sanne C., Hissink Muller, Petra C.E., Homan-van der Veen, Jenneke, Jacobs, Monique A.M., Kamps, Arvid W.A., Ketharanathan, Naomi, van der Kuip, Martijn, Kuijpers, Taco W., Legger, Elizabeth G., Lo-A-Njoe, Shirley, Manshande, Meindert E., Miedema, Carien J., Obihara, Charlie C., Olivieira, Gideon O., Oudshoorn, Annemarie, Peeters, Esther J.E., Petru, Ronald, Pijnenburg, Marielle W.H., Rook, Denise, Schilleman, Kim, Schopmeijer, Rian, Slotboom, David, van der Steen, Manouk, Stol, Kim, Thomasse, Yolande E.M., Tissing, Wim J.E., van den Tweel, Xandra W., Vastert, Sebastiaan J., Verbeek, Anne B., Vernooij-van Langen, Annette M.M., Wieringa, Jantien W., Wildenbeest, Joanne G., de Wildt, Saskia N., and van Woerden, Christiaan

Published
2023
Full Text
View/download PDF

9. Human TH17 cells engage gasdermin E pores to release IL-1α on NLRP3 inflammasome activation

Author

Chao, Ying-Yin, Puhach, Alisa, Frieser, David, Arunkumar, Mahima, Lehner, Laurens, Seeholzer, Thomas, Garcia-Lopez, Albert, van der Wal, Marlot, Fibi-Smetana, Silvia, Dietschmann, Axel, Sommermann, Thomas, Ćiković, Tamara, Taher, Leila, Gresnigt, Mark S., Vastert, Sebastiaan J., van Wijk, Femke, Panagiotou, Gianni, Krappmann, Daniel, Groß, Olaf, and Zielinski, Christina E.

Published
2023
Full Text
View/download PDF

10. Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort study

Author

Ohm, Milou, van Straalen, Joeri W., Zijlstra, Marieke, de Joode-Smink, Gerrie, Sellies, Anne Jasmijn, Swart, Joost F., Vastert, Sebastiaan J., van Montfrans, Joris M., Bartels, Marije, van Royen-Kerkhof, Annet, Wildenbeest, Joanne G., Lindemans, Caroline A., Wolters, Victorien M., Wennink, Roos A.W., de Boer, Joke H., Knol, Mirjam J., Heijstek, Marloes W., Sanders, Elisabeth A.M., Verduyn-Lunel, Frans M., Berbers, Guy A.M., Wulffraat, Nico M., and Jansen, Marc H.A.

Published
2023
Full Text
View/download PDF

14. N6-methyladenosine promotes TNF mRNA degradation in CD4+ T lymphocytes.

Author

Vroonhoven, Ellen C N van, Picavet, Lucas W, Scholman, Rianne C, Sijbers, Lyanne J P M, Kievit, Corlinda R E, Dungen, Noortje A M van den, Mokry, Michal, Evers, Anouk, Lebbink, Robert J, Mocholi, Enric, Coffer, Paul J, Calis, Jorg J A, Vastert, Sebastiaan J, and Loosdregt, Jorg van

Subjects
RNA modification & restriction, TUMOR necrosis factors, T cells, RNA methylation, LYMPHOCYTE transformation
Abstract

N6-methyladenosine (m6A) is a RNA modification that can regulate post-transcriptional processes including RNA stability, translation, splicing, and nuclear export. In CD4+ lymphocytes, m6A modifications have been demonstrated to play a role in early differentiation processes. The role of m6A in CD4+ T cell activation and effector function remains incompletely understood. To assess the role of m6A in CD4+ T lymphocyte activation and function, we assessed the transcriptome-wide m6A landscape of human primary CD4+ T cells by methylated RNA immunoprecipitation sequencing. Stimulation of the T cells impacted the m6A pattern of hundreds of transcripts including tumor necrosis factor (TNF). m6A methylation was increased on TNF messenger RNA (mRNA) after activation, predominantly in the 3′ untranslated region of the transcript. Manipulation of m6A levels in primary human T cells, the directly affected the expression of TNF. Furthermore, we identified that the m6A reader protein YTHDF2 binds m6A-methylated TNF mRNA, and promotes its degradation. Taken together, this study demonstrates that TNF expression in CD4+ T lymphocytes is regulated via m6A and YTHDF2, thereby providing novel insight into the regulation of T cell effector functions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors in juvenile idiopathic arthritis.

Author

Florax, Anna A, Doeleman, Martijn J H, Roock, Sytze de, van der Linden, Naomi, Schatorjé, Ellen, Currie, Gillian, Marshall, Deborah A, Jzerman, Maarten J I, Yeung, Rae S M, Benseler, Susanne M, Vastert, Sebastiaan J, Wulffraat, Nico M, Swart, Joost F, Kip, Michelle M A, and Consortia, for UCAN-CAN DU and UCAN CURE

Subjects
ANTI-inflammatory agents, JUVENILE idiopathic arthritis, HOSPITAL charges, RESEARCH funding, TERMINATION of treatment, RETROSPECTIVE studies, LONGITUDINAL method, MEDICAL records, ACQUISITION of data, ELECTRONIC health records
Abstract

Objective To quantify differences in hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors (TNFi) in JIA patients. Methods This was a retrospective analysis of prospectively collected data from electronic medical records of paediatric JIA patients treated with TNFi, which were immediately discontinued, spaced (increased treatment interval) or tapered (reduced subsequent doses). Costs of hospital-associated resource use (consultations, medication, radiology procedures, laboratory testing, procedures under general anaesthesia, hospitalization) and associated travel costs and productivity losses were quantified during clinically inactive disease until TNFi withdrawal (pre-withdrawal period) and compared with costs during the first and second year after withdrawal initiation (first and second year post-withdrawal). Results Fifty-six patients were included of whom 26 immediately discontinued TNFi, 30 spaced and zero tapered. Mean annual costs were €9165/patient on active treatment (pre-withdrawal) and decreased significantly to €5063/patient (−44.8%) and €6569/patient (−28.3%) in the first and second year post-withdrawal, respectively (P  < 0.05). Of these total annual costs, travel costs plus productivity losses were €834/patient, €1180/patient, and €1320/patient in the three periods respectively. Medication comprised 80.7%, 61.5% and 72.4% of total annual costs in the pre-withdrawal, first and second year post-withdrawal period, respectively. Conclusion In the first two years after initiating withdrawal, the total annual costs were decreased compared with the pre-withdrawal period. However, cost reductions were lower in the second year compared with the first year post-withdrawal, primarily due to restarting or intensifying biologics. To support biologic withdrawal decisions, future research should assess the full long-term societal cost impacts, and include all biologics. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. m6A Reader YTHDC1 Impairs Respiratory Syncytial Virus Infection by Downregulating Membrane CX3CR1 Expression

Author

Picavet, Lucas W., primary, van Vroonhoven, Ellen C. N., additional, Scholman, Rianne C., additional, Smits, Yesper T. H., additional, Banerjee, Rupa, additional, Besteman, Sjanna B., additional, Viveen, Mattheus C., additional, van der Vlist, Michiel M., additional, Tanenbaum, Marvin E., additional, Lebbink, Robert J., additional, Vastert, Sebastiaan J., additional, and van Loosdregt, Jorg, additional

Published
2024
Full Text
View/download PDF

18. N6-methyladenosine promotes TNF mRNA degradation in CD4+T lymphocytes

Author

van Vroonhoven, Ellen C N, Picavet, Lucas W, Scholman, Rianne C, Sijbers, Lyanne J P M, Kievit, Corlinda R E, van den Dungen, Noortje A M, Mokry, Michal, Evers, Anouk, Lebbink, Robert J, Mocholi, Enric, Coffer, Paul J, Calis, Jorg J A, Vastert, Sebastiaan J, and van Loosdregt, Jorg

Abstract

N6-methyladenosine (m6A) is a RNA modification that can regulate post-transcriptional processes including RNA stability, translation, splicing, and nuclear export. In CD4+lymphocytes, m6A modifications have been demonstrated to play a role in early differentiation processes. The role of m6A in CD4+T cell activation and effector function remains incompletely understood. To assess the role of m6A in CD4+T lymphocyte activation and function, we assessed the transcriptome-wide m6A landscape of human primary CD4+T cells by methylated RNA immunoprecipitation sequencing. Stimulation of the T cells impacted the m6A pattern of hundreds of transcripts including tumor necrosis factor (TNF). m6A methylation was increased on TNFmessenger RNA (mRNA) after activation, predominantly in the 3′ untranslated region of the transcript. Manipulation of m6A levels in primary human T cells, the directly affected the expression of TNF. Furthermore, we identified that the m6A reader protein YTHDF2 binds m6A-methylated TNFmRNA, and promotes its degradation. Taken together, this study demonstrates that TNF expression in CD4+T lymphocytes is regulated via m6A and YTHDF2, thereby providing novel insight into the regulation of T cell effector functions.This study demonstrates that tumor necrosis factor expression in CD4+ T lymphocytes is regulated via N6-methyladenosine and YTHDF2, thereby providing novel insight into the regulation of T cell effector functions.T helper cells are immune cells of the adaptive immune system. These cells are activated by antigen presenting cells that have engulfed invading pathogens. When the T helper cell is activated, it will produce and excrete signaling molecules (cytokines) that activate other immune cells in order to eradicate these pathogens. Cytokines are formed after translation of RNA molecules that encode for these cytokines. In this study it was found that a modification (N6-methyladenosine) on RNA molecules is involved in the regulation of the life cycle of these RNA molecules. It was found that the degradation of RNA encoding for cytokine tumor necrosis factor (TNF) was mediated through N6-methyladenosine and its “reader” protein YTHDF2 in activated T helper cells. As TNF promotes inflammation, reduction of TNF production through this mechanism dampens the immune response and therefore prevents chronic inflammation.

Published
2024
Full Text
View/download PDF

19. Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts

Author

MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Arts-assistenten Kinderen, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, Leavis, Helen L, van Daele, Paul L A, Mulders-Manders, Catharina, Michels, Renée, Rutgers, Abraham, Legger, Elizabeth, Bijl, Marc, Hak, Elisabeth A, Lam-Tse, Wai-Kwan, Bonte-Mineur, Femke, Fretter, Peter, Simon, Anna, van Paassen, Pieter, van der Goes, Marlies, Flendrie, Marcel, Vercoutere, Ward, van Lieshout, Antoine W T, Leek, Arjen, Vastert, Sebastiaan J, Tas, Sander W, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Arts-assistenten Kinderen, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, Leavis, Helen L, van Daele, Paul L A, Mulders-Manders, Catharina, Michels, Renée, Rutgers, Abraham, Legger, Elizabeth, Bijl, Marc, Hak, Elisabeth A, Lam-Tse, Wai-Kwan, Bonte-Mineur, Femke, Fretter, Peter, Simon, Anna, van Paassen, Pieter, van der Goes, Marlies, Flendrie, Marcel, Vercoutere, Ward, van Lieshout, Antoine W T, Leek, Arjen, Vastert, Sebastiaan J, and Tas, Sander W

Published
2024

21. m6A Reader YTHDC1 Impairs Respiratory Syncytial Virus Infection by Downregulating Membrane CX3CR1 Expression

Author

CTI, Immuno/reuma onderzoek 3 (Loosdregt), Infection & Immunity, CTI Lab support, Arts-assistenten Kinderen, MMB Research line 2, CTI Van der Vlist, MMB Research line 3a, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, CTI Research, Picavet, Lucas W., van Vroonhoven, Ellen C.N., Scholman, Rianne C., Smits, Yesper T.H., Banerjee, Rupa, Besteman, Sjanna B., Viveen, Mattheus C., van der Vlist, Michiel M., Tanenbaum, Marvin E., Lebbink, Robert J., Vastert, Sebastiaan J., van Loosdregt, Jorg, CTI, Immuno/reuma onderzoek 3 (Loosdregt), Infection & Immunity, CTI Lab support, Arts-assistenten Kinderen, MMB Research line 2, CTI Van der Vlist, MMB Research line 3a, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, CTI Research, Picavet, Lucas W., van Vroonhoven, Ellen C.N., Scholman, Rianne C., Smits, Yesper T.H., Banerjee, Rupa, Besteman, Sjanna B., Viveen, Mattheus C., van der Vlist, Michiel M., Tanenbaum, Marvin E., Lebbink, Robert J., Vastert, Sebastiaan J., and van Loosdregt, Jorg

Published
2024

22. CBP/P300 Inhibition Impairs CD4+ T Cell Activation: Implications for Autoimmune Disorders

Author

Immuno/reuma onderzoek 3 (Loosdregt), Infection & Immunity, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), CTI Lab support, CDL Onderzoek Pasterkamp, Experimentele Afd. Cardiologie 1, Child Health, Circulatory Health, Immunologie/Reumatologie, CTI Research, Picavet, Lucas Wilhelmus, Samat, Anoushka A K, Calis, Jorg, Nijhuis, Lotte, Scholman, Rianne, Mokry, Michal, Tough, David F, Prinjha, Rabinder K, Vastert, Sebastiaan J, van Loosdregt, Jorg, Immuno/reuma onderzoek 3 (Loosdregt), Infection & Immunity, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), CTI Lab support, CDL Onderzoek Pasterkamp, Experimentele Afd. Cardiologie 1, Child Health, Circulatory Health, Immunologie/Reumatologie, CTI Research, Picavet, Lucas Wilhelmus, Samat, Anoushka A K, Calis, Jorg, Nijhuis, Lotte, Scholman, Rianne, Mokry, Michal, Tough, David F, Prinjha, Rabinder K, Vastert, Sebastiaan J, and van Loosdregt, Jorg

Published
2024

23. Serum proteomics reveals hemophagocytic lymphohistiocytosis-like phenotype in a subset of patients with multisystem inflammatory syndrome in children

Author

CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Genetica Sectie Genoomdiagnostiek, Tulling, Adam J, Holierhoek, Marloes G, Jansen-Hoogendijk, Anja M, Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J, Oostenbrink, Rianne, Buysse, Corinne M P, Bannier, Michiel A G E, Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C, Jacobs, Monique A M, Kamps, Arvid W A, van der Linden, Jan W, Lebon, Ankie, Oudshoorn, Johanna H, Tramper-Stranders, Gerdien A, Vastert, Sebastiaan J, Wieringa, Jantien W, Terheggen-Lagro, Suzanne W J, Wildenbeest, Joanne G, von Asmuth, Erik G J, van den Akker, Erik B, van Gijn, Marielle E, Lugthart, Gertjan, Buddingh, Emilie P, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Genetica Sectie Genoomdiagnostiek, Tulling, Adam J, Holierhoek, Marloes G, Jansen-Hoogendijk, Anja M, Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J, Oostenbrink, Rianne, Buysse, Corinne M P, Bannier, Michiel A G E, Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C, Jacobs, Monique A M, Kamps, Arvid W A, van der Linden, Jan W, Lebon, Ankie, Oudshoorn, Johanna H, Tramper-Stranders, Gerdien A, Vastert, Sebastiaan J, Wieringa, Jantien W, Terheggen-Lagro, Suzanne W J, Wildenbeest, Joanne G, von Asmuth, Erik G J, van den Akker, Erik B, van Gijn, Marielle E, Lugthart, Gertjan, and Buddingh, Emilie P

Published
2024

24. Get Spliced: Uniting Alternative Splicing and Arthritis

Author

Infection & Immunity, Immuno/reuma onderzoek 3 (Loosdregt), Immunologie/Reumatologie, Immuno/reuma onderzoek 1 (Vastert), CTI Van Loosdregt, Child Health, CTI Research, van Haaren, Maurice J.H., Steller, Levina Bertina, Vastert, Sebastiaan J., Calis, Jorg J.A., van Loosdregt, Jorg, Infection & Immunity, Immuno/reuma onderzoek 3 (Loosdregt), Immunologie/Reumatologie, Immuno/reuma onderzoek 1 (Vastert), CTI Van Loosdregt, Child Health, CTI Research, van Haaren, Maurice J.H., Steller, Levina Bertina, Vastert, Sebastiaan J., Calis, Jorg J.A., and van Loosdregt, Jorg

Published
2024

25. Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis

Author

Infection & Immunity, Immunologie/Reumatologie, Immuno/reuma onderzoek 1 (Vastert), CTI Van Loosdregt, Child Health, Vastert, Sebastiaan J., Canny, Susan P., Canna, Scott W., Schneider, Rayfel, Mellins, Elizabeth D., Infection & Immunity, Immunologie/Reumatologie, Immuno/reuma onderzoek 1 (Vastert), CTI Van Loosdregt, Child Health, Vastert, Sebastiaan J., Canny, Susan P., Canna, Scott W., Schneider, Rayfel, and Mellins, Elizabeth D.

Published
2024

26. Management of adult-onset Still's disease:evidence- and consensus-based recommendations by experts

Author

Leavis, Helen L., van Daele, Paul L.A., Mulders-Manders, Catharina, Michels, Renée, Rutgers, Abraham, Legger, Elizabeth, Bijl, Marc, Hak, Elisabeth A., Lam-Tse, Wai Kwan, Bonte-Mineur, Femke, Fretter, Peter, Simon, Anna, van Paassen, Pieter, van der Goes, Marlies C., Flendrie, Marcel, Vercoutere, Ward, van Lieshout, Antoine W.T., Leek, Arjen, Vastert, Sebastiaan J., Tas, Sander W., Leavis, Helen L., van Daele, Paul L.A., Mulders-Manders, Catharina, Michels, Renée, Rutgers, Abraham, Legger, Elizabeth, Bijl, Marc, Hak, Elisabeth A., Lam-Tse, Wai Kwan, Bonte-Mineur, Femke, Fretter, Peter, Simon, Anna, van Paassen, Pieter, van der Goes, Marlies C., Flendrie, Marcel, Vercoutere, Ward, van Lieshout, Antoine W.T., Leek, Arjen, Vastert, Sebastiaan J., and Tas, Sander W.

Abstract

Objectives: Adult-onset Still's disease (AOSD) is a rare condition characterized by fevers, rash, and arthralgia/arthritis; most doctors treating AOSD in the Netherlands treat <5 patients per year. Currently, there is no internationally accepted treatment guideline for AOSD. The objectives of this study were to conduct a Delphi panel aimed at reaching consensus about diagnostic and treatment strategies for patients with AOSD and to use the outcomes as a basis for a treatment algorithm. Methods: The Delphi panel brought together 18 AOSD experts: rheumatologists, internists and paediatricians. The Delphi process consisted of three rounds. In the first two rounds, online lists of questions and statements were completed. In the third round, final statements were discussed during a virtual meeting and a final vote took place. Consensus threshold was set at 80%. Two targeted literature searches were performed identifying the level of evidence of the consensus-based statements. Results: Consensus was reached on 29 statements, including statements related to diagnosis and diagnostic tests, definition of response and remission, the therapy, the use of methotrexate and tapering of treatment. The panel consented on reduction of the use of glucocorticoids to avoid side effects, and preferred the use of biologics over conventional treatment. The role of IL-1 and IL-6 blocking agents was considered important in the treatment of AOSD. Conclusion: In this Delphi panel, a high level of consensus was achieved on recommendations for diagnosis and therapy of AOSD that can serve as a basis for a treatment guideline.

Published
2024

27. Recombinant Interleukin-1 Receptor antagonist is an effective first-line treatment strategy in new-onset systemic Juvenile Idiopathic Arthritis, irrespective of HLA-DRB1 background and IL1RN variants

Author

Immuno/reuma onderzoek 1 (Vastert), Infection & Immunity, Immuno/reuma onderzoek 5 (Vastert2), Child Health, CTI Vastert, Genetica Sectie Genoomdiagnostiek, Cancer, Genetica Medische Informatica, CTI Van Loosdregt, Immuno/reuma patientenzorg, CTI Research, Immuno/reuma onderzoek 3 (Loosdregt), Immunologie/Reumatologie, Erkens, Remco G A, Calis, Jorg J A, Verwoerd, Anouk, De Roock, Sytze, Ter Haar, Nienke M, Den Engelsman, Gerda, Van der Veken, Lars T, Ernst, Robert F, Van Deutekom, Hanneke W M, Pickering, Alex, Scholman, Rianne C, Jansen, Marc H A, Swart, Joost F, Sinha, Rashmi, Roth, Johannes, Schulert, Grant S, Grom, Alexei A, Van Loosdregt, Jorg, Vastert, Sebastiaan J, Immuno/reuma onderzoek 1 (Vastert), Infection & Immunity, Immuno/reuma onderzoek 5 (Vastert2), Child Health, CTI Vastert, Genetica Sectie Genoomdiagnostiek, Cancer, Genetica Medische Informatica, CTI Van Loosdregt, Immuno/reuma patientenzorg, CTI Research, Immuno/reuma onderzoek 3 (Loosdregt), Immunologie/Reumatologie, Erkens, Remco G A, Calis, Jorg J A, Verwoerd, Anouk, De Roock, Sytze, Ter Haar, Nienke M, Den Engelsman, Gerda, Van der Veken, Lars T, Ernst, Robert F, Van Deutekom, Hanneke W M, Pickering, Alex, Scholman, Rianne C, Jansen, Marc H A, Swart, Joost F, Sinha, Rashmi, Roth, Johannes, Schulert, Grant S, Grom, Alexei A, Van Loosdregt, Jorg, and Vastert, Sebastiaan J

Published
2024

29. Get Spliced: Uniting Alternative Splicing and Arthritis.

Author

van Haaren, Maurice J. H., Steller, Levina Bertina, Vastert, Sebastiaan J., Calis, Jorg J. A., and van Loosdregt, Jorg

Subjects
ALTERNATIVE RNA splicing, GENETIC regulation, GENE expression, RNA sequencing, AUTOIMMUNE diseases, RNA splicing
Abstract

Immune responses demand the rapid and precise regulation of gene protein expression. Splicing is a crucial step in this process; ~95% of protein-coding gene transcripts are spliced during mRNA maturation. Alternative splicing allows for distinct functional regulation, as it can affect transcript degradation and can lead to alternative functional protein isoforms. There is increasing evidence that splicing can directly regulate immune responses. For several genes, immune cells display dramatic changes in isoform-level transcript expression patterns upon activation. Recent advances in long-read RNA sequencing assays have enabled an unbiased and complete description of transcript isoform expression patterns. With an increasing amount of cell types and conditions that have been analyzed with such assays, thousands of novel transcript isoforms have been identified. Alternative splicing has been associated with autoimmune diseases, including arthritis. Here, GWASs revealed that SNPs associated with arthritis are enriched in splice sites. In this review, we will discuss how alternative splicing is involved in immune responses and how the dysregulation of alternative splicing can contribute to arthritis pathogenesis. In addition, we will discuss the therapeutic potential of modulating alternative splicing, which includes examples of spliceform-based biomarkers for disease severity or disease subtype, splicing manipulation using antisense oligonucleotides, and the targeting of specific immune-related spliceforms using antibodies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. CBP/P300 Inhibition Impairs CD4+ T Cell Activation: Implications for Autoimmune Disorders.

Author

Picavet, Lucas Wilhelmus, Samat, Anoushka A. K., Calis, Jorg, Nijhuis, Lotte, Scholman, Rianne, Mokry, Michal, Tough, David F., Prinjha, Rabinder K., Vastert, Sebastiaan J., and van Loosdregt, Jorg

Subjects
T cells, AUTOIMMUNE diseases, JUVENILE idiopathic arthritis, CD4 antigen, CREB protein, LYSINE
Abstract

T cell activation is critical for an effective immune response against pathogens. However, dysregulation contributes to the pathogenesis of autoimmune diseases, including Juvenile Idiopathic Arthritis (JIA). The molecular mechanisms underlying T cell activation are still incompletely understood. T cell activation promotes the acetylation of histone 3 at Lysine 27 (H3K27ac) at enhancer and promoter regions of proinflammatory cytokines, thereby increasing the expression of these genes which is essential for T cell function. Co-activators E1A binding protein P300 (P300) and CREB binding protein (CBP), collectively known as P300/CBP, are essential to facilitate H3K27 acetylation. Presently, the role of P300/CBP in human CD4+ T cells activation remains incompletely understood. To assess the function of P300/CBP in T cell activation and autoimmune disease, we utilized iCBP112, a selective inhibitor of P300/CBP, in T cells obtained from healthy controls and JIA patients. Treatment with iCBP112 suppressed T cell activation and cytokine signaling pathways, leading to reduced expression of many proinflammatory cytokines, including IL-2, IFN-γ, IL-4, and IL-17A. Moreover, P300/CBP inhibition in T cells derived from the inflamed synovium of JIA patients resulted in decreased expression of similar pathways and preferentially suppressed the expression of disease-associated genes. This study underscores the regulatory role of P300/CBP in regulating gene expression during T cell activation while offering potential insights into the pathogenesis of autoimmune diseases. Our findings indicate that P300/CBP inhibition could potentially be leveraged for the treatment of autoimmune diseases such as JIA in the future. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts.

Author

Leavis, Helen L, Daele, Paul L A van, Mulders-Manders, Catharina, Michels, Renée, Rutgers, Abraham, Legger, Elizabeth, Bijl, Marc, Hak, Elisabeth A, Lam-Tse, Wai-Kwan, Bonte-Mineur, Femke, Fretter, Peter, Simon, Anna, Paassen, Pieter van, Goes, Marlies C van der, Flendrie, Marcel, Vercoutere, Ward, Lieshout, Antoine W T van, Leek, Arjen, Vastert, Sebastiaan J, and Tas, Sander W

Subjects
RHEUMATOID arthritis diagnosis, BIOTHERAPY, RHEUMATOID arthritis treatment, CONSENSUS (Social sciences), WORLD Wide Web, RESEARCH funding, QUESTIONNAIRES, METHOTREXATE, TREATMENT effectiveness, DESCRIPTIVE statistics, EVIDENCE-based medicine, DELPHI method, RHEUMATOLOGISTS, GLUCOCORTICOIDS, EVALUATION
Abstract

Objectives Adult-onset Still's disease (AOSD) is a rare condition characterized by fevers, rash, and arthralgia/arthritis; most doctors treating AOSD in the Netherlands treat <5 patients per year. Currently, there is no internationally accepted treatment guideline for AOSD. The objectives of this study were to conduct a Delphi panel aimed at reaching consensus about diagnostic and treatment strategies for patients with AOSD and to use the outcomes as a basis for a treatment algorithm. Methods The Delphi panel brought together 18 AOSD experts: rheumatologists, internists and paediatricians. The Delphi process consisted of three rounds. In the first two rounds, online lists of questions and statements were completed. In the third round, final statements were discussed during a virtual meeting and a final vote took place. Consensus threshold was set at 80%. Two targeted literature searches were performed identifying the level of evidence of the consensus-based statements. Results Consensus was reached on 29 statements, including statements related to diagnosis and diagnostic tests, definition of response and remission, the therapy, the use of methotrexate and tapering of treatment. The panel consented on reduction of the use of glucocorticoids to avoid side effects, and preferred the use of biologics over conventional treatment. The role of IL-1 and IL-6 blocking agents was considered important in the treatment of AOSD. Conclusion In this Delphi panel, a high level of consensus was achieved on recommendations for diagnosis and therapy of AOSD that can serve as a basis for a treatment guideline. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. m 6 A Reader YTHDC1 Impairs Respiratory Syncytial Virus Infection by Downregulating Membrane CX3CR1 Expression.

Author

Picavet, Lucas W., van Vroonhoven, Ellen C. N., Scholman, Rianne C., Smits, Yesper T. H., Banerjee, Rupa, Besteman, Sjanna B., Viveen, Mattheus C., van der Vlist, Michiel M., Tanenbaum, Marvin E., Lebbink, Robert J., Vastert, Sebastiaan J., and van Loosdregt, Jorg

Subjects
RESPIRATORY syncytial virus infections, PARAINFLUENZA viruses, CHEMOKINE receptors, RNA methylation, RESPIRATORY infections in children, RESPIRATORY syncytial virus infection vaccines, LIFE cycles (Biology)
Abstract

Respiratory syncytial virus (RSV) is the most prevalent cause of acute lower respiratory infection in young children. Currently, the first RSV vaccines are approved by the FDA. Recently, N6-methyladenosine (m6A) RNA methylation has been implicated in the regulation of the viral life cycle and replication of many viruses, including RSV. m6A methylation of RSV RNA has been demonstrated to promote replication and prevent anti-viral immune responses by the host. Whether m6A is also involved in viral entry and whether m6A can also affect RSV infection via different mechanisms than methylation of viral RNA is poorly understood. Here, we identify m6A reader YTH domain-containing protein 1 (YTHDC1) as a novel negative regulator of RSV infection. We demonstrate that YTHDC1 abrogates RSV infection by reducing the expression of RSV entry receptor CX3C motif chemokine receptor 1 (CX3CR1) on the cell surface of lung epithelial cells. Altogether, these data reveal a novel role for m6A methylation and YTHDC1 in the viral entry of RSV. These findings may contribute to the development of novel treatment options to control RSV infection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts

Author

Leavis, Helen L, primary, van Daele, Paul L A, additional, Mulders-Manders, Catharina, additional, Michels, Renée, additional, Rutgers, Abraham, additional, Legger, Elizabeth, additional, Bijl, Marc, additional, Hak, Elisabeth A, additional, Lam-Tse, Wai-Kwan, additional, Bonte-Mineur, Femke, additional, Fretter, Peter, additional, Simon, Anna, additional, van Paassen, Pieter, additional, van der Goes, Marlies, additional, Flendrie, Marcel, additional, Vercoutere, Ward, additional, van Lieshout, Antoine W T, additional, Leek, Arjen, additional, Vastert, Sebastiaan J, additional, and Tas, Sander W, additional

Published
2023
Full Text
View/download PDF

37. Recombinant Interleukin‐1 Receptor antagonist is an effective first‐line treatment strategy in new‐onset systemic Juvenile Idiopathic Arthritis, irrespective of HLA‐DRB1 background and IL1RN variants

Author

Erkens, Remco G. A., primary, Calis, Jorg J. A., additional, Verwoerd, Anouk, additional, De Roock, Sytze, additional, Ter Haar, Nienke M., additional, Den Engelsman, Gerda, additional, Van der Veken, Lars T., additional, Ernst, Robert F., additional, Van Deutekom, Hanneke W. M., additional, Pickering, Alex, additional, Scholman, Rianne C., additional, Jansen, Marc H. A., additional, Swart, Joost F., additional, Sinha, Rashmi, additional, Roth, Johannes, additional, Schulert, Grant S., additional, Grom, Alexei A., additional, Van Loosdregt, Jorg, additional, and Vastert, Sebastiaan J., additional

Published
2023
Full Text
View/download PDF

38. N6-Methyladenosine Directly Regulates CD40L Expression in CD4+ T Lymphocytes

Author

van Vroonhoven, Ellen C. N., primary, Picavet, Lucas W., additional, Scholman, Rianne C., additional, van den Dungen, Noortje A. M., additional, Mokry, Michal, additional, Evers, Anouk, additional, Lebbink, Robert J., additional, Calis, Jorg J. A., additional, Vastert, Sebastiaan J., additional, and van Loosdregt, Jorg, additional

Published
2023
Full Text
View/download PDF

39. Recombinant Interleukin‐1 Receptor Antagonist Is an Effective First‐Line Treatment Strategy in New‐Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA‐DRB1 Background and IL1RN Variants.

Author

Erkens, Remco G. A., Calis, Jorg J. A., Verwoerd, Anouk, De Roock, Sytze, Ter Haar, Nienke M., Den Engelsman, Gerda, Van der Veken, Lars T., Ernst, Robert F., Van Deutekom, Hanneke W. M., Pickering, Alex, Scholman, Rianne C., Jansen, Marc H. A., Swart, Joost F., Sinha, Rashmi, Roth, Johannes, Schulert, Grant S., Grom, Alexei A., Van Loosdregt, Jorg, and Vastert, Sebastiaan J.

Subjects
THERAPEUTIC use of cytokines, HLA-B27 antigen, SEQUENCE analysis, BIOLOGICAL products, INTERLEUKIN-1, CELL receptors, JUVENILE idiopathic arthritis, INTERSTITIAL lung diseases, ALLELES, EOSINOPHILIA, DESCRIPTIVE statistics, RECOMBINANT proteins, LONGITUDINAL method, DISEASE remission
Abstract

Objective: Human leukocyte antigen (HLA)‐DRB1*15:01 has been recently associated with interstitial lung disease (LD), eosinophilia, and drug reactions in systemic juvenile idiopathic arthritis (sJIA). Additionally, genetic variants in IL1RN have been linked to poor response to anakinra. We sought to reproduce these findings in a prospective cohort study of patients with new‐onset sJIA treated with anakinra as first‐line therapy. Methods: HLA and IL1RN risk alleles were identified via whole‐genome sequencing. Treatment responses and complications were compared between carriers versus noncarriers. Results: Seventeen of 65 patients (26%) carried HLA‐DRB1*15:01, comparable with the general population, and there was enrichment for HLA‐DRB1*11:01, a known risk locus for sJIA. The rates of clinical inactive disease (CID) at 6 months, 1 year, and 2 years were generally high, irrespective of HLA‐DRB1 or IL1RN variants, but significantly lower in carriers of an HLA‐DRB1*11:01 allele. One patient, an HLA‐DRB1*15:01 carrier, developed sJIA‐LD. Of the three patients with severe drug reactions to biologics, one carried HLA‐DRB1*15:01. The prevalence of eosinophilia did not significantly differ between HLA‐DRB1*15:01 carriers and noncarriers at disease onset (6.2% vs 14.9%, P = 0.67) nor after the start of anakinra (35.3% vs 37.5% in the first 2 years of disease). Conclusion: We observed high rates of CID using anakinra as first‐line treatment irrespective of HLA‐DRB1 or IL1RN variants. Only one of the 17 HLA‐DRB1*15:01 carriers developed sJIA‐LD, and of the three patients with drug reactions to biologics, only one carried HLA‐DRB1*15:01. Although thorough monitoring for the development of drug hypersensitivity and refractory disease courses in sJIA, including sJIA‐LD, remains important, our data support the early start of biologic therapy in patients with new‐onset sJIA irrespective of HLA‐DRB1 background or IL1RN variants. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. The 4th NextGen Therapies for SJIA and MAS: part 1 the elephant in the room: diagnostic/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still's disease

Author

CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, Nigrovic, Peter A, de Benedetti, Fabrizio, Kimura, Yukiko, Lovell, Daniel J, Vastert, Sebastiaan J, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, Nigrovic, Peter A, de Benedetti, Fabrizio, Kimura, Yukiko, Lovell, Daniel J, and Vastert, Sebastiaan J

Published
2023

41. Withdrawing biologics in non-systemic JIA:what matters to pediatric rheumatologists?

Author

van Til, Janine A, Kip, Michelle M A, Schatorjé, Ellen J H, Currie, Gillian, Twilt, Marinka, Benseler, Susanne M, Swart, Joost F, Vastert, Sebastiaan J, Wulffraat, Nico, Yeung, Rae S M, Groothuis-Oudshoorn, C G M Karin, Warta, Sanne, Marshall, Deborah A, IJzerman, Maarten J, van Til, Janine A, Kip, Michelle M A, Schatorjé, Ellen J H, Currie, Gillian, Twilt, Marinka, Benseler, Susanne M, Swart, Joost F, Vastert, Sebastiaan J, Wulffraat, Nico, Yeung, Rae S M, Groothuis-Oudshoorn, C G M Karin, Warta, Sanne, Marshall, Deborah A, and IJzerman, Maarten J

Abstract

OBJECTIVE: Approximately one third of children with JIA receive biologic therapy, but evidence on biologic therapy withdrawal is lacking. This study aims to increase our understanding of whether and when pediatric rheumatologists postpone a decision to withdraw biologic therapy in children with clinically inactive non-systemic JIA.METHODS: A survey containing questions about background characteristics, treatment patterns, minimum treatment time with biologic therapy, and 16 different patient vignettes, was distributed among 83 pediatric rheumatologists in Canada and the Netherlands. For each vignette, respondents were asked whether they would withdraw biologic therapy at their minimum treatment time, and if not, how long they would continue biologic therapy. Statistical analysis included descriptive statistics, logistic and interval regression analysis.RESULTS: Thirty-three pediatric rheumatologists completed the survey (40% response rate). Pediatric rheumatologists are most likely to postpone the decision to withdraw biologic therapy when the child and/or parents express a preference for continuation (OR 6.3; p < 0.001), in case of a flare in the current treatment period (OR 3.9; p = 0.001), and in case of uveitis in the current treatment period (OR 3.9; p < 0.001). On average, biologic therapy withdrawal is initiated 6.7 months later when the child or parent prefer to continue treatment.CONCLUSION: Patient's and parents' preferences were the strongest driver of a decision to postpone biologic therapy withdrawal in children with clinically inactive non-systemic JIA and prolongs treatment duration. These findings highlight the potential benefit of a tool to support pediatric rheumatologists, patients and parents in decision making, and can help inform its design.

Published
2023

42. Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands:a real-world data analysis

Author

Kip, Michelle M A, de Roock, Sytze, Currie, Gillian, Marshall, Deborah A, Grazziotin, Luiza R, Twilt, Marinka, Yeung, Rae S M, Benseler, Susanne M, Vastert, Sebastiaan J, Wulffraat, Nico, Swart, Joost F, IJzerman, Maarten J, Kip, Michelle M A, de Roock, Sytze, Currie, Gillian, Marshall, Deborah A, Grazziotin, Luiza R, Twilt, Marinka, Yeung, Rae S M, Benseler, Susanne M, Vastert, Sebastiaan J, Wulffraat, Nico, Swart, Joost F, and IJzerman, Maarten J

Abstract

OBJECTIVE: To investigate medication prescription patterns among children with juvenile idiopathic arthritis (JIA), including duration, sequence and reasons for medication discontinuation.METHODS: This study is a single-center, retrospective analysis of prospective data from electronic medical records of JIA patients receiving systemic therapy aged 0-18 years between 1 April 2011 and 31 March 2019. Patient characteristics (age, gender, JIA subtype) and medication prescriptions were extracted and analyzed using descriptive statistics, Sankey diagrams, and Kaplan-Meier survival methods.RESULTS: Over a median of 4.2 years follow-up, the 20 different medicines analyzed were prescribed as monotherapy (n = 15) or combination therapy (n = 48 unique combinations) among 236 patients. In non-systemic JIA, synthetic disease-modifying-anti-rheumatic-drugs (DMARDs) were prescribed to almost all patients (99.5%), and always included methotrexate. In contrast, 43.9% of non-systemic JIA patients received a biologic DMARD (mostly adalimumab or etanercept), ranging from 30.9% for oligoarticular persistent ANA-positive JIA, to 90.9% for polyarticular RF-positive JIA. Among systemic JIA, 91.7% received a biologic DMARD (always including anakinra). When analyzing medication prescriptions according to their class, 33.1% involved combination therapy. In 56.8% of patients, subsequent treatment lines were initiated after unsuccessful first-line treatment, resulting in 68 unique sequences. Remission was the most common reason for DMARD discontinuation (44.7%), followed by adverse events (28.9%), and ineffectiveness (22.1%).CONCLUSION: This paper reveals the complexity of pharmacological treatment in JIA, as indicated by: the variety of mono- and combination therapies prescribed, substantial variation in medication prescriptions between subtypes, most patients receiving ≥2 treatment lines, and the large number of unique treatment sequences.

Published
2023

43. Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children from Wild-type to Population Immunity: A Prospective Multicenter Cohort Study with Real-time Reporting

Author

Epi Infectieziekten Team 1, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Infectieziekten patientenzorg, Infectieziekten onderzoek2 (Wildenbeest), Tulling, Adam J., Lugthart, Gertjan, Mooij, Miriam G., Brackel, Caroline L.H., Terheggen-Lagro, Suzanne W.J., Oostenbrink, Rianne, Buysse, Corinne M.P., Hashimoto, Simone, Armbrust, Wineke, Bannier, Michiel A.G.E., Bekhof, Jolita, Van Gameren-Oosterom, Helma B., Hendriks, Han, Van Houten, Marlies A., Van Der Linden, Jan W., Lebon, Ankie, Van Onzenoort-Bokken, Lonneke, Tramper-Stranders, Gerdien A., Van Veen, Mirjam, Von Asmuth, Erik G.J., Buddingh, Emilie P., Van Der Aa, Leontien B., Van Aerde, Koen J., Auffarth-Smedema, Bettina, Bart, Ingeborg Y., Beek, Cherise, Bechan, Gitanjali I., Van Den Berg, J. Merlijn, Boonstra, Venje H., Breukels, Mijke, Brinkman, Danielle M.C., Bruijning-Verhagen, Patricia C.J.L., De Crom, Stephanie C., Ernst-Kruis, Margot R., Fraaij, Pieter L.A., Goris, Joyce, Groeneweg, Michael, Gruppen, Mariken, Hammer, Sanne C., Hissink Muller, Petra C.E., Homan-Van Der Veen, Jenneke, Jacobs, Monique A.M., Kamps, Arvid W.A., Ketharanathan, Naomi, Van Der Kuip, Martijn, Kuijpers, Taco W., Legger, Elizabeth G., Lo-A-Njoe, Shirley, Manshande, Meindert E., Miedema, Carien J., Obihara, Charlie C., Olivieira, Gideon O., Oudshoorn, Annemarie, Peeters, Esther J.E., Petru, Ronald, Pijnenburg, Marielle W.H., Rook, Denise, Schilleman, Kim, Schopmeijer, Rian, Slotboom, David, Van Der Steen, Manouk, Stol, Kim, Thomasse, Yolande E.M., Tissing, Wim J.E., Van Den Tweel, Xandra W., Vastert, Sebastiaan J., Verbeek, Anne B., Vernooij-Van Langen, Annette M.M., Wieringa, Jantien W., Wildenbeest, Joanne G., De Wildt, Saskia N., Van Woerden, Christiaan, Epi Infectieziekten Team 1, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Infectieziekten patientenzorg, Infectieziekten onderzoek2 (Wildenbeest), Tulling, Adam J., Lugthart, Gertjan, Mooij, Miriam G., Brackel, Caroline L.H., Terheggen-Lagro, Suzanne W.J., Oostenbrink, Rianne, Buysse, Corinne M.P., Hashimoto, Simone, Armbrust, Wineke, Bannier, Michiel A.G.E., Bekhof, Jolita, Van Gameren-Oosterom, Helma B., Hendriks, Han, Van Houten, Marlies A., Van Der Linden, Jan W., Lebon, Ankie, Van Onzenoort-Bokken, Lonneke, Tramper-Stranders, Gerdien A., Van Veen, Mirjam, Von Asmuth, Erik G.J., Buddingh, Emilie P., Van Der Aa, Leontien B., Van Aerde, Koen J., Auffarth-Smedema, Bettina, Bart, Ingeborg Y., Beek, Cherise, Bechan, Gitanjali I., Van Den Berg, J. Merlijn, Boonstra, Venje H., Breukels, Mijke, Brinkman, Danielle M.C., Bruijning-Verhagen, Patricia C.J.L., De Crom, Stephanie C., Ernst-Kruis, Margot R., Fraaij, Pieter L.A., Goris, Joyce, Groeneweg, Michael, Gruppen, Mariken, Hammer, Sanne C., Hissink Muller, Petra C.E., Homan-Van Der Veen, Jenneke, Jacobs, Monique A.M., Kamps, Arvid W.A., Ketharanathan, Naomi, Van Der Kuip, Martijn, Kuijpers, Taco W., Legger, Elizabeth G., Lo-A-Njoe, Shirley, Manshande, Meindert E., Miedema, Carien J., Obihara, Charlie C., Olivieira, Gideon O., Oudshoorn, Annemarie, Peeters, Esther J.E., Petru, Ronald, Pijnenburg, Marielle W.H., Rook, Denise, Schilleman, Kim, Schopmeijer, Rian, Slotboom, David, Van Der Steen, Manouk, Stol, Kim, Thomasse, Yolande E.M., Tissing, Wim J.E., Van Den Tweel, Xandra W., Vastert, Sebastiaan J., Verbeek, Anne B., Vernooij-Van Langen, Annette M.M., Wieringa, Jantien W., Wildenbeest, Joanne G., De Wildt, Saskia N., and Van Woerden, Christiaan

Published
2023

44. N6-Methyladenosine Directly Regulates CD40L Expression in CD4+ T Lymphocytes

Author

CTI Eijkelkamp, CTI Van Loosdregt, Infection & Immunity, Experimentele Afdeling Longziekten 2, CDL Research analisten, Cancer, CDL Onderzoek Pasterkamp, Experimentele Afd. Cardiologie 1, Child Health, Circulatory Health, MMB Research line 3a, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, CTI Research, Immuno/reuma onderzoek 3 (Loosdregt), van Vroonhoven, Ellen C.N., Picavet, Lucas W., Scholman, Rianne C., van den Dungen, Noortje A.M., Mokry, Michal, Evers, Anouk, Lebbink, Robert J., Calis, Jorg J.A., Vastert, Sebastiaan J., van Loosdregt, Jorg, CTI Eijkelkamp, CTI Van Loosdregt, Infection & Immunity, Experimentele Afdeling Longziekten 2, CDL Research analisten, Cancer, CDL Onderzoek Pasterkamp, Experimentele Afd. Cardiologie 1, Child Health, Circulatory Health, MMB Research line 3a, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, CTI Research, Immuno/reuma onderzoek 3 (Loosdregt), van Vroonhoven, Ellen C.N., Picavet, Lucas W., Scholman, Rianne C., van den Dungen, Noortje A.M., Mokry, Michal, Evers, Anouk, Lebbink, Robert J., Calis, Jorg J.A., Vastert, Sebastiaan J., and van Loosdregt, Jorg

Published
2023

45. Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort study

Author

Immuno/reuma onderzoek 7 (Swart), Infection & Immunity, Arts-assistenten Kinderen, Immuno/reuma patientenzorg, Child Health, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Cluster B, Haematologie patientenzorg, Poli Van Creveldkliniek Medisch, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, SCT patientenzorg, Regenerative Medicine and Stem Cells, MDL, MS Oogheelkunde, MS Reumatologie/Immunologie/Infectie, Onderzoek, MMB Medische Staf, Immuno/reuma ERN, Ohm, Milou, van Straalen, Joeri W, Zijlstra, Marieke, de Joode-Smink, Gerrie, Jasmijn Sellies, Anne, Swart, Joost F, Vastert, Sebastiaan J, van Montfrans, Joris M, Bartels, Marije, van Royen-Kerkhof, Annet, Wildenbeest, Joanne G, Lindemans, Caroline A, Wolters, Victorien, Wennink, Roos A W, de Boer, Joke H, Knol, Mirjam J, Heijstek, Marloes W, Sanders, Elisabeth A M, Verduyn-Lunel, Frans M, Berbers, Guy A M, Wulffraat, Nico M, Jansen, Marc H A, Immuno/reuma onderzoek 7 (Swart), Infection & Immunity, Arts-assistenten Kinderen, Immuno/reuma patientenzorg, Child Health, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Cluster B, Haematologie patientenzorg, Poli Van Creveldkliniek Medisch, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, SCT patientenzorg, Regenerative Medicine and Stem Cells, MDL, MS Oogheelkunde, MS Reumatologie/Immunologie/Infectie, Onderzoek, MMB Medische Staf, Immuno/reuma ERN, Ohm, Milou, van Straalen, Joeri W, Zijlstra, Marieke, de Joode-Smink, Gerrie, Jasmijn Sellies, Anne, Swart, Joost F, Vastert, Sebastiaan J, van Montfrans, Joris M, Bartels, Marije, van Royen-Kerkhof, Annet, Wildenbeest, Joanne G, Lindemans, Caroline A, Wolters, Victorien, Wennink, Roos A W, de Boer, Joke H, Knol, Mirjam J, Heijstek, Marloes W, Sanders, Elisabeth A M, Verduyn-Lunel, Frans M, Berbers, Guy A M, Wulffraat, Nico M, and Jansen, Marc H A

Published
2023

46. What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis?: A best-worst scaling survey

Author

Immuno/reuma onderzoek 7 (Swart), Infection & Immunity, Immuno/reuma patientenzorg, Child Health, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Immuno/reuma ERN, Currie, Gillian R, Groothuis-Oudshoorn, Catherina G M, Twilt, Marinka, Kip, Michelle M A, IJzerman, Maarten J, Benseler, Susanne M, Swart, Joost F, Vastert, Sebastiaan J, Wulffraat, Nico M, Yeung, Rae, Marshall, Deborah A, Immuno/reuma onderzoek 7 (Swart), Infection & Immunity, Immuno/reuma patientenzorg, Child Health, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Immuno/reuma ERN, Currie, Gillian R, Groothuis-Oudshoorn, Catherina G M, Twilt, Marinka, Kip, Michelle M A, IJzerman, Maarten J, Benseler, Susanne M, Swart, Joost F, Vastert, Sebastiaan J, Wulffraat, Nico M, Yeung, Rae, and Marshall, Deborah A

Published
2023

47. Epigenetic changes in inflammatory arthritis monocytes contribute to disease and can be targeted by JAK inhibition

Author

CMM Groep Coffer, CDL Cluster Onderzoek en Onderwijs, CTI Van Loosdregt, CMM Sectie Stem Cells, Onderzoek, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, CDL Onderzoek Pasterkamp, Experimentele Afd. Cardiologie 1, Child Health, Circulatory Health, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, CTI Van Wijk, CTI Research, Immuno/reuma onderzoek 3 (Loosdregt), Peeters, Janneke G C, Boltjes, Arjan, Scholman, Rianne C, Vervoort, Stephin J, Coffer, Paul J, Mokry, Michal, Vastert, Sebastiaan J, van Wijk, Femke, van Loosdregt, Jorg, CMM Groep Coffer, CDL Cluster Onderzoek en Onderwijs, CTI Van Loosdregt, CMM Sectie Stem Cells, Onderzoek, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, CDL Onderzoek Pasterkamp, Experimentele Afd. Cardiologie 1, Child Health, Circulatory Health, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, CTI Van Wijk, CTI Research, Immuno/reuma onderzoek 3 (Loosdregt), Peeters, Janneke G C, Boltjes, Arjan, Scholman, Rianne C, Vervoort, Stephin J, Coffer, Paul J, Mokry, Michal, Vastert, Sebastiaan J, van Wijk, Femke, and van Loosdregt, Jorg

Published
2023

48. Conventional dendritic cells type 1 are strongly enriched, quiescent and relatively tolerogenic in local inflammatory arthritis

Author

CTI, CDL Cluster Onderzoek en Onderwijs, CTI Vastert, Infection & Immunity, CDL Onderzoek Pasterkamp, Experimentele Afd. Cardiologie 1, Child Health, Circulatory Health, Immuno/reuma patientenzorg, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, CTI Research, Cancer, Immuno/reuma onderzoek 3 (Loosdregt), CTI Van Wijk, Boltjes, Arjan, Samat, Anoushka Ashok Kumar, Plantinga, Maud, Mokry, Michal, Castelijns, Bas, Swart, Joost F., Vastert, Sebastiaan J., Creyghton, Menno, Nierkens, Stefan, van Loosdregt, Jorg, van Wijk, Femke, CTI, CDL Cluster Onderzoek en Onderwijs, CTI Vastert, Infection & Immunity, CDL Onderzoek Pasterkamp, Experimentele Afd. Cardiologie 1, Child Health, Circulatory Health, Immuno/reuma patientenzorg, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, CTI Research, Cancer, Immuno/reuma onderzoek 3 (Loosdregt), CTI Van Wijk, Boltjes, Arjan, Samat, Anoushka Ashok Kumar, Plantinga, Maud, Mokry, Michal, Castelijns, Bas, Swart, Joost F., Vastert, Sebastiaan J., Creyghton, Menno, Nierkens, Stefan, van Loosdregt, Jorg, and van Wijk, Femke

Published
2023

49. Patients' and parents' satisfaction to improve patient care in JIA: factors determining acceptable symptom state measured with JAMAR

Author

Reumatologie patientenzorg, Immuno/reuma onderzoek 1 (Vastert), Child Health, Infection & Immunity, CTI Van Loosdregt, Immunologie/Reumatologie, Immuno/reuma ERN, Immuno/reuma patientenzorg, Del Giudice, Emanuela, de Roock, Sytze, Vastert, Sebastiaan J, Wulffraat, Nico M, Swart, Joost F, van Dijkhuizen, Evert H P, Reumatologie patientenzorg, Immuno/reuma onderzoek 1 (Vastert), Child Health, Infection & Immunity, CTI Van Loosdregt, Immunologie/Reumatologie, Immuno/reuma ERN, Immuno/reuma patientenzorg, Del Giudice, Emanuela, de Roock, Sytze, Vastert, Sebastiaan J, Wulffraat, Nico M, Swart, Joost F, and van Dijkhuizen, Evert H P

Published
2023

50. Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis

Author

Immuno/reuma onderzoek 1 (Vastert), Infection & Immunity, Child Health, CTI Van Loosdregt, Immuno/reuma onderzoek 5 (Vastert2), Immunologie/Reumatologie, Cluster B, Immuno/reuma ERN, Regenerative Medicine and Stem Cells, Immuno/reuma patientenzorg, Kip, Michelle M A, de Roock, Sytze, Currie, Gillian, Marshall, Deborah A, Grazziotin, Luiza R, Twilt, Marinka, Yeung, Rae S M, Benseler, Susanne M, Vastert, Sebastiaan J, Wulffraat, Nico, Swart, Joost F, IJzerman, Maarten J, Immuno/reuma onderzoek 1 (Vastert), Infection & Immunity, Child Health, CTI Van Loosdregt, Immuno/reuma onderzoek 5 (Vastert2), Immunologie/Reumatologie, Cluster B, Immuno/reuma ERN, Regenerative Medicine and Stem Cells, Immuno/reuma patientenzorg, Kip, Michelle M A, de Roock, Sytze, Currie, Gillian, Marshall, Deborah A, Grazziotin, Luiza R, Twilt, Marinka, Yeung, Rae S M, Benseler, Susanne M, Vastert, Sebastiaan J, Wulffraat, Nico, Swart, Joost F, and IJzerman, Maarten J

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results